[Protective action of leukinferin during radiotherapy of oncologic patients].
In clinical observation on 248 patients with breast cancer IIb-III-b stages given radiotherapy on breast gland, parasternal and axillary-subclavian regions (total doses 40 Gr for each) before mastectomy was shown, that use LF im 2-3 times a week through the course of therapy decreases statistically significant pancytopenia, induced by radiation. Quantity leukocytes was even increase in a process of therapy. Frequency of anemia and lyphopenia was decreased almost 3 times. E-RFC were depressed also more slight, then in the group without immunocorrection and after mastectomy practically, restored. IFN-gamma production by T-lymphocytes was not changed and essentially more high then in the comparative group. The presented data are shown, that LF provides a defensive action on hematological indices and immune effectors function in oncological patients during radiotherapy.
Rasskazchikova
E S
ES
Semashko Moscow Medical Stomatological Institute.
Kuznetsov
V P
VP
Korobkova
L I
LI
Beliaev
D L
DL
Babaiants
A A
AA
Vel'sher
Z L
ZL
D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D007109:Immunity / Q000187:drug effects* / Q000528:radiation effects; D007370:Interferon Type I / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000096:biosynthesis; D007958:Leukocyte Count / Q000187:drug effects / Q000528:radiation effects; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D012397:Rosette Formation; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000528:radiation effects
D007370:Interferon Type I; D011837:Radiation-Protective Agents; D007371:Interferon-gamma
Zashchitnoe deĭstvie leĭkinferona pri luchevom lechenii onkologicheskikh bol'nykh.